GrafixPL PRIME Evaluation Case Study
Primary Purpose
Diabetic Foot Ulcer
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
GrafixPL PRIME
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Foot Ulcer
Eligibility Criteria
Inclusion Criteria:
- Able to provide informed consent
- 18-90 years of age
- Chronic foot ulceration below the ankle - persistent for 30 days or longer
- Ankle Brachial Index (ABI) >0.5 (Bedside ABI is acceptable for screening purposes as the formal imaging ABI may not be resulted prior to surgery)
Exclusion Criteria:
- Unable to provide informed consent
- <18 or >90 years of age
- History of poor compliance with follow-up visits
- Gangrene
- Untreated Osteomyelitis
- Widespread malignancy
- Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines
- Currently Pregnant or planning pregnancy during the course of intended participation in the study
- Is nursing or actively lactating
Sites / Locations
- UT Southwestern Medical Center at Dallas
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
GrafixPL PRIME
Arm Description
Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
Outcomes
Primary Outcome Measures
Number of Participants With Complete Closure of the Index Ulcer
Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.
Secondary Outcome Measures
Time to Closure
Total Adverse Events
There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - "closed wounds" and "not closed wounds." Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.
Full Information
NCT ID
NCT03742440
First Posted
November 9, 2018
Last Updated
July 20, 2023
Sponsor
University of Texas Southwestern Medical Center
Collaborators
Osiris Therapeutics
1. Study Identification
Unique Protocol Identification Number
NCT03742440
Brief Title
GrafixPL PRIME Evaluation Case Study
Official Title
GrafixPL PRIME Evaluation Case Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
November 20, 2018 (Actual)
Primary Completion Date
March 1, 2020 (Actual)
Study Completion Date
March 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center
Collaborators
Osiris Therapeutics
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators plan to evaluate healing in a cohort of patients with chronic wounds (n=40) that receive optimal treatment including serial wound debridement and off-loading with total contact casts or a boot and GrafixPL PRIME. In addition, the investigators will collect data on other potential confounding factors that could affect healing such as medications, tobacco, nutrition, comorbidities, diabetes control, infection, perfusion, and activity. Wound healing, including wound size and adverse events will be evaluated. The objective of this study is to understand the use of this product to evaluate wound healing in 40 patients.
Detailed Description
Screening and Enrollment:
Review and sign the Informed Consent and HIPAA Authorization
Review the inclusion and exclusion criteria
If the subject qualifies for the study, they will participate in the following procedures (weekly visits, +/-4 days):
Visit 0:
Demographics (such as age, gender, race or ethnicity)
Medical/Surgical and Social History, Current Antibiotics.
Laboratory Results
Vascular - ABI
Neurological evaluation - Monofilament and VPT
Vitals - Sitting blood pressure and Pulse rate, Height/Weight, and BMI
Wound debridement
eKare - Wound imaging measurement
Application of GrafixPL PRIME
Current Antibiotics
Offloading
Adverse Events
Source documentation
Visits 1 - 11:
Wound debridement
eKare - Wound imaging measurement
Application of GrafixPL PRIME
Current Antibiotics
Offloading
Adverse Events
Source documentation
Visit 12/End of Study (EOS) Visit:
Wound debridement
eKare - Wound imaging measurement
Current Antibiotics
Offloading
Adverse Events
Source documentation (End of Study will occur on the date the subject is healed)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GrafixPL PRIME
Arm Type
Other
Arm Description
Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
Intervention Type
Biological
Intervention Name(s)
GrafixPL PRIME
Intervention Description
GrafixPL PRIME
Primary Outcome Measure Information:
Title
Number of Participants With Complete Closure of the Index Ulcer
Description
Complete closure of the index ulcer, defined as 100% re-epithelialization as determined by the Investigator by week 12 or the End of Treatment Visit.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Time to Closure
Time Frame
12 weeks
Title
Total Adverse Events
Description
There was no control arm in this study - everyone enrolled received treatment. Analysis of these data was separated into two groups - "closed wounds" and "not closed wounds." Wounds that closed achieved full epithelialization within the 12 week study time frame. Wounds that did not close did not achieve full epithelialization by the end of study visit.
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to provide informed consent
18-90 years of age
Chronic foot ulceration below the ankle - persistent for 30 days or longer
Ankle Brachial Index (ABI) >0.5 (Bedside ABI is acceptable for screening purposes as the formal imaging ABI may not be resulted prior to surgery)
Exclusion Criteria:
Unable to provide informed consent
<18 or >90 years of age
History of poor compliance with follow-up visits
Gangrene
Untreated Osteomyelitis
Widespread malignancy
Active alcohol or substance abuse such as cocaine, heroin, or methamphetamines
Currently Pregnant or planning pregnancy during the course of intended participation in the study
Is nursing or actively lactating
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lawrence Lavery, DPM MPH
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
UT Southwestern Medical Center at Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
12. IPD Sharing Statement
Learn more about this trial
GrafixPL PRIME Evaluation Case Study
We'll reach out to this number within 24 hrs